MEDICARE FORM

AVASTIN™ (bevacizumab)
ALYMSYS™ (bevacizumab-maly)
AVZIVI™ (bevacizumab-tnjn)
MVASI™ (bevacizumab-awwb)
VEGZELMA® (bevacizumab-adcd)
ZIRABEV™ (bevacizumab-bvzr)
Medication Precertification Request

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
Phone: 1-866-503-0857 (TTY: 711)
FAX: 1-844-268-7263

For other lines of business:
Please use other form.

Note: Alymsys, Avastin, Avzivi and Vegzelma are non-preferred. The preferred products are Mvasi and Zirabev.

Please indicate: ☐ Start of treatment: Start date ____/____/____ ☐ Continuation of therapy, Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		DOB:	
Address:		City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	Email:	
Patient Current Weight: ____ lbs or ____ kgs Patient Height: ____ inches or ____ cms			Allergies:	

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured:

Medicare: ☐ Yes ☐ No If yes, provide ID #: **Medicaid:** ☐ Yes ☐ No If yes, provide ID #:

C. PRESCRIBER INFORMATION

First Name:		Last Name:		*(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.	
Address:			City:	State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	

Specialty *(Check one):* ☐ **Oncologist** ☐ **Ophthalmologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other
Name: _____
Address: _____
City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____
NPI: _____

E. PRODUCT INFORMATION

Request is for: ☐ **AVASTIN (bevacizumab)** ☐ **ALYMSYS™ (bevacizumab-maly)** ☐ **AVZIVI™ (bevacizumab-tnjn)**
☐ **MVASI (bevacizumab-awwb)** ☐ **VEGZELMA (bevacizumab-adcd)** ☐ **ZIRABEV (bevacizumab-bvzr)**

Dose: _____ **Frequency:** _____ **HCPCS Code:** _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: _____ **Secondary ICD Code:** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

For Initiation Requests (clinical documentation required for all requests):

Ophthalmic disorders:

☐ Yes ☐ No Is this request for Avastin treatment?
→ ☐ Yes ☐ No Has the patient tried and failed treatment with Avastin due to a documented intolerable adverse event (e.g., rash, nausea, vomiting)?
☐ Yes ☐ No Was the adverse event unexpected and not attributed to the active ingredient as described in the prescribing information?

Please select the diagnosis:

☐ Choroidal neovascularization (CNV) (including myopic choroidal neovascularization (mCNV), angioid streaks, choroiditis [including choroiditis secondary to ocular histoplasmosis], idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, pseudoxanthoma elasticum, and trauma)
☐ Diabetic macular edema ☐ Macular edema following retinal vein occlusion (RVO) ☐ Neovascular (wet) Age-Related Macular Degeneration (AMD)
☐ Neovascular glaucoma ☐ Polypoidal choroidal vasculopathy ☐ Proliferative diabetic retinopathy ☐ Retinopathy of prematurity

Continued on next page

aetna®

MEDICARE FORM

AVASTIN™ (bevacizumab)
ALYMSYS™ (bevacizumab-maly)
AVZIVI™ (bevacizumab-tnjn)
MVASI™ (bevacizumab-awwb)
VEGZELMA® (bevacizumab-adcd)
ZIRABEV™ (bevacizumab-bvzr)
Medication Precertification Request

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
Phone: 1-866-503-0857 (TTY: 711)
FAX: 1-844-268-7263

For other lines of business:
Please use other form

Note: Alymsys, Avastin, Avzivi and Vegzelma are non-preferred. The preferred products are Mvasi and Zirabev.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests

Oncology indications:

Note: Alymsys, Avastin, Avzivi and Vegzelma are non-preferred. The preferred products are Mvasi and Zirabev.

☐ Yes ☐ No Has the patient had prior therapy with requested product within the last 365 days?

☐ Yes ☐ No Has the patient had a trial and failure, intolerance, or contraindication to any of the following? (select all that apply)

☐ Mvasi (bevacizumab-awwb) ☐ Zirabev (bevacizumab-bvzr)

Please explain if there are any other medical reason(s) that the patient cannot use any of the following preferred products when indicated for the patient's diagnosis? (select all that apply)

☐ Mvasi (bevacizumab-awwb) ☐ Zirabev (bevacizumab-bvzr)

Please select the diagnosis:

☐ Ampullary Adenocarcinoma
- → Please indicate the type of ampullary adenocarcinoma which applies to the patient's disease: ☐ Intestinal-type ☐ Other
- ☐ Yes ☐ No Does the patient have progressive, unresectable, or metastatic disease?
  - → Please select: ☐ progressive disease ☐ unresectable disease ☐ metastatic disease ☐ none of the above

☐ Anaplastic glioma

☐ Angiosarcoma
- → ☐ Yes ☐ No Will the requested medication be given as a single agent therapy?

☐ Breast cancer
- → ☐ Yes ☐ No Does the patient have recurrent or metastatic disease?
  - → Please select: ☐ recurrent disease ☐ metastatic disease ☐ none of the above

☐ Cervical cancer
- → ☐ Yes ☐ No Does the patient have persistent, recurrent, or metastatic disease?
  - → Please select: ☐ persistent disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above

☐ Colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma

☐ Diffuse high grade gliomas

☐ Glioblastoma

☐ Endometrial carcinoma
- → ☐ Yes ☐ No Does the patient have progressive, advanced, recurrent, or metastatic disease?
  - → Please select: ☐ progressive disease ☐ advanced disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above

☐ Epithelial ovarian cancer (including carcinosarcoma [malignant mixed Müllerian tumors], clear cell carcinoma, mucinous carcinoma, endometrioid carcinoma, serous carcinoma, and malignant sex cord-stromal tumors)

☐ Fallopian tube cancer

☐ Gastric cancer

☐ Hepatocellular carcinoma
- → ☐ Yes ☐ No Does the patient have unresectable or metastatic disease?
  - → Please select: ☐ unresectable disease ☐ metastatic disease ☐ none of the above
- ☐ Yes ☐ No Will the requested drug be used as initial treatment?
- ☐ Yes ☐ No Will the requested medication be given in combination with atezolizumab (Tecentriq)?

☐ IDH mutant astrocytoma (WHO Grade 2, 3, or 4)

☐ Intracranial and spinal ependymoma (excludes subependymoma)

☐ Limited and extensive brain metastases

☐ Low-grade (WHO Grade 1 or 2) Glioma

☐ Medulloblastoma

☐ Meningiomas

Continued on next page.

aetna®

MEDICARE FORM

AVASTIN™ (bevacizumab)
ALYMSYS™ (bevacizumab-maly)
AVZIVI™ (bevacizumab-tnjn)
MVASI™ (bevacizumab-awwb)
VEGZELMA® (bevacizumab-adcd)
ZIRABEV™ (bevacizumab-bvzr)
Medication Precertification Request

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
Phone: 1-866-503-0857 (TTY: 711)
FAX: 1-844-268-7263

For other lines of business:
Please use other form

Note: Alymsys, Avastin, Avzivi, and Vegzelma are non-preferred. The preferred products are Mvasi and Zirabev.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests

☐ Mesothelioma
→ Please indicate the type of mesothelioma which applies to the patient's disease:
☐ malignant pleural mesothelioma ☐ malignant peritoneal mesothelioma ☐ pericardial mesothelioma ☐ tunica vaginalis testis mesothelioma
☐ other
Please indicate the place in therapy in which the requested drug will be used:
☐ First-line treatment
→ ☐ Yes ☐ No Will the requested medication be given in combination with pemetrexed (Alimta) and either cisplatin (Platinol) or carboplatin (Paraplatin), followed by single-agent maintenance bevacizumab?
☐ Yes ☐ No Does the patient have unresectable disease?
☐ Subsequent treatment
→ Please select the requested regimen:
☐ In combination with pemetrexed (Alimta) and either cisplatin (Platinol) or carboplatin (Paraplatin)
→ ☐ Yes ☐ No Has the patient received immunotherapy as first-line treatment?
☐ In combination with atezolizumab (Tecentriq)
☐ Other

☐ Metastatic spine tumors
☐ Necrosis of central nervous system due to exposure to ionizing radiation
☐ Non-squamous non-small cell lung cancer (NSCLC)
→ ☐ Yes ☐ No Does the patient have recurrent, advanced, metastatic, or unresectable disease?
→ Please select: ☐ recurrent disease ☐ advanced disease ☐ metastatic disease ☐ unresectable disease ☐ none of the above
☐ Oligodendroglioma (WHO Grade 2 or 3)
☐ Primary central nervous system lymphoma
☐ Primary peritoneal cancer
☐ Renal cell carcinoma
→ ☐ Yes ☐ No Does the patient have relapsed or stage IV disease? ☐ relapsed disease ☐ stage IV disease ☐ none of the above
☐ Small bowel adenocarcinoma
☐ Solitary fibrous tumor or hemangiopericytoma
→ ☐ Yes ☐ No Will the requested medication be given in combination with temozolomide (Temodar)?
☐ Uterine neoplasms
→ ☐ Yes ☐ No Does the patient have progressive, advanced, recurrent, or metastatic disease?
→ Please select: ☐ progressive disease ☐ advanced disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above
☐ Vaginal cancer
→ ☐ Yes ☐ No Does the patient have persistent, recurrent, or metastatic disease?
→ Please select: ☐ persistent disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above
☐ Vulvar squamous cell carcinoma
→ ☐ Yes ☐ No Does the patient have unresectable locally advanced, recurrent, or metastatic disease?
→ Please select: ☐ unresectable locally advanced disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above

For Continuation Requests (clinical documentation required for all requests):

Ophthalmic disorders:
☐ Yes ☐ No Has the patient demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss)?

Oncology indications:
☐ Yes ☐ No Has the patient experienced an unacceptable toxicity or disease progression while on the current regimen?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required)*: _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.